Consistency of Bordetella pertussis vaccine seed strains and potency of whole-cell pertussis vaccine still in use in Poland

Biologicals

Volumn 42, Issue 2, 2014, Pages 123-127

  Zawadka, Monika ^a   Mosiej, Ewa ^a   Polak, Maciej ^a   Krysztopa Grzybowska, Katarzyna ^a   Moskała, Bozena ^b   Rokosz Chudziak, Natalia ^a   Rabczenko, Daniel ^a   Augustynowicz, Ewa ^a   Lutyńska, Anna ^a  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

^b IBSS BIOMED SA   (Poland)

Author keywords

Bordetella pertussis; Pertussis increase; Potency; Vaccine strains; Whole cell pertussis vaccine

Indexed keywords

PERTUSSIS VACCINE;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BORDETELLA PERTUSSIS; DRUG POTENCY; DRUG USE; FIM2 1 GENE; FIM3 1 GENE; GENE SEQUENCE; MOUSE; NONHUMAN; POLAND; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PRN1 GENE; PTXA2 GENE; PTXC1 GENE; PTXP1 GENE; PULSED FIELD GEL ELECTROPHORESIS; SEROTYPING; TCFA2 GENE; IMMUNOLOGY;

BORDETELLA PERTUSSIS;

BORDETELLA PERTUSSIS; ELECTROPHORESIS, GEL, PULSED-FIELD; ELECTROPHORESIS, POLYACRYLAMIDE GEL; PERTUSSIS VACCINE; POLAND;

EID: 84896492775     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2013.11.006     Document Type: Article

References (26)

1. Mattoo S., Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella Subspecies. Clin Microbiol Rev 2005, 18:326-382.
2. Gzyl A., Augustynowicz E., Rabczenko D., Gniadek G., Slusarczyk J. Pertussis in Poland. Int J Epidemiol 2004, 33:358-365.
3. Tan T., Trindade E., Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J 2005, 24:S10-S18.
4. Gzyl A., Augustynowicz E., van Loo I., Slusarczyk J. Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine 2001, 20:299-303.
5. Mooi F.R., van der Maas N.A.T., de Melker H.E. Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin. Epidemiol Infect 2013, 1-10.
6. Cherry J.D. Why do pertussis vaccines fail?. Pediatrics 2012, 129:968-970.
7. Sheridan S.L., Ware R.S., Grimwood K., Lambert S.B. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA-JAm Med Assoc 2012, 308:454-456.
8. de Greeff S.C., de Melker H.E., van Gageldonk P.G.M., Schellekens J.F.P., van der Klis F.R.M., Mollema L., et al. Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PloS One 2010, 5:e14183.
9. Gzyl A., Augustynowicz E., Rabczenko D., Gniadek G., Slusarczyk J. Potency of pertussis component in the DTP vaccine-an overview of three decade study in Poland. Biol J Int Assoc Biol Stand 2004, 32:129-137.
10. Zieliński A., Rosińska M., Czarkowski M., Rudowska J. The effectiveness of vaccination with whole-cell pertussis vaccine by age group in Poland 1996-2001. Scand J Infect Dis 2004, 36:114-118.
11. NIPH-NIH - Department of Epidemiology. Infectious diseases and poisonings in Poland in 2012, Available from: [cited 2013 March 11]. http://www.pzh.gov.pl/oldpage/epimeld/2012/INF_12_12B.
12. Advani A., Donnelly D., Hallander H. Reference system for characterization of Bordetella pertussis pulsed-field gel electrophoresis profiles. JClin Microbiol 2004, 42:2890-2897.
13. Weber C., Boursaux-Eude C., Coralie G., Caro V., Guiso N. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. JClin Microbiol 2001, 39:4396-4403.
14. Caro V., Njamkepo E., Van Amersfoorth S.C.M., Mooi F.R., Advani A., Hallander H.O., et al. Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microbes Infect Inst Pasteur 2005, 7:976-982.
15. Mosiej E., Augustynowicz E., Zawadka M., Dabrowski W., Lutyńska A. Strain variation among Bordetella pertussis isolates circulating in Poland after 50 years of whole-cell pertussis vaccine use. JClin Microbiol 2011, 49:1452-1457.
16. Mooi F.R., van Loo I.H.M., van Gent M., He Q., Bart M.J., Heuvelman K.J., et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis 2009, 15:1206-1213.
17. van Loo I.H.M., Heuvelman K.J., King A.J., Mooi F.R. Multilocus sequence typing of Bordetella pertussis based on surface protein genes. JClin Microbiol 2002, 40:1994-2001.
18. Assay of pertussis vaccines. Eur Pharmacopoeia 2008, 213-214. 7th ed.
19. Requirements for diphteria, tetanus, and pertussis and combined vaccines 1990, World Health Organization, Technical Report Series no. 800.
20. Njamkepo E., Rimlinger F., Thiberge S., Guiso N. Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine 2002, 20:1290-1294.
21. Kamachi K., Fukuda T., Han H.-J., Toyoizumi-Ajisaka H., Mochida K., Konda T., et al. Genetic verification of Bordetella pertussis seed strains used for production ofJapanese acellular pertussis vaccines. Biol J Int Assoc Biol Stand 2010, 38:290-293.
22. Kendrick P.L., Eldering G., Dixon M.K., Misner J. Mouse Protection tests in the study of pertussis vaccine: a comparative series using the intracerebral route for Challenge. Am J Public Health Nations Health 1947, 37:803-810.
23. VACCINATION against whooping-cough; relation between protection in children and results of laboratory tests; a report to the Whooping-cough Immunization Committee of the Medical Research Council and to the medical officers of health for Cardiff, Leeds, Leyton, Manchester, Middlesex, Oxford, Poole, Tottenham, Walthamstow, and Wembley. Br Med J 1956, 2:454-462.
24. Dellepiane N., Griffiths E., Milstien J.B. New challenges in assuring vaccine quality. Bull World Health Organ 2000, 78:155-162.
25. World Health Organization. Informal consultation on the control of pertussis with whole cell and acellular vaccines. Geneva: WHO/V&B/99.03.
26. Milstien J.B., Gellin B.G., Kane M., di Fabio J.L., Homma A. Global DTP manufacturing capacity and capability. Status report: January 1995. Vaccine 1996, 14:313-320.